Pacira Pharma (PCRX): Cutting Estimates On EXPAREL Data - Wedbush

October 19, 2016 8:06 AM EDT
Get Alerts PCRX Hot Sheet
Price: $33.35 +0.45%

Rating Summary:
    10 Buy, 6 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade PCRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Wedbush analyst, Liana Moussatos, cut her price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $93 from $109 after the Symphony Health Q3 EXPAREL estimate came in ~4% below consensus leading the analyst to cut estimates.

The new 12-month price target is calculated based on sum-of-parts for each drug/indication combination using a 30% annual discount from peak annual revenue projections and 1-10x multiple, depending on stage of development to reflect risk.

No change to the Outperform rating.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $34.65 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Liana Moussatos

Add Your Comment